Purity 99% HPLC
RUO: Research Use Designation Only. Not for human or veterinary use.

Tesofensine (also known as NS2330 or TE) is a molecular compound which has been researched as a way to treat obesity via appetite suppression. Tesofensine increases transmission of 3 monoaminergic neurotransmitters in the brain which have been shown to be successful in weight management in animal studies.

Originally studied for its effect on Parkinson’s and Alzheimer’s, Tesofensine was noted to have powerful weight-loss and appetite suppression abilities, so much so that test subjects were stopped from further using the compound because they were losing significant weight.

Tesofensine offers researchers a direct link to elevating metabolism and enhancing weight loss in research subjects.

Pre-Clinical Research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing.

Tesofensine also appears to promote cognition, learning, and memory via the cholinergic pathway. This leads to increases in BDNF which stimulates neuron growth and has been shown in research to offer benefits to subjects with depression, cognitive decline, and certain neurological conditions.

Tesofensine Structure

CAS Number: 195875-84-8 (Deprecated: 402856-42-2)
Chemical Formula C₁₇H₂₃CL₂NO
Molar Mass: 3.277 g/mol
Amino Acid Sequence: Not a Peptide
PubChem CID: 11370864

Notes: Tesofensine is available in a powder format. Capsules can be used to facilitate the handling and use of the Tesofensine powder. Tesofensine acts as a triple monoamine reuptake inhibitor. This works exclusively with the central nervous system in a targeted approach with translates to reduced appetite and increased energy expenditure.

Tesofensine has shown significant ability to control glucose in rats and may offer an enhanced insulin response to sugar load. This helps reduce fat storage and shifts the metabolism in subjects.

Tesofensine has strong research showing that the compound has beneficial effects on cognition, memory and neurogenesis. Research in rats shows an increase in BDNF which plays a role in brain cell survival and synaptic transmission.
Research is ongoing to get Tesofensine to market as an anti-obesity drug,

Stability and Bioavailability: Tesofensine exhibits good oral and subcutaneous bioavailability in mice.

Tesofensine Insights and Referenced Citations:

• Bodyweight Loss, Body Composition Change – Subjects lost double the amount of weight as that of currently approved weight loss drugs. No significant increases in Blood Pressure.

Lancet. 2008 Nov 29;372 (9653):1906-1913.

• Enhanced Energy Production and Reduced Appetite – Tesofensine
  Increased weight loss after 2 weeks treatment. TE also induced higher ratings of satiety and fullness which resulted in lower food intake. TE also increased 24-hour fat oxidation as opposed to placebo. Pronounced effect on appetite and slight effect on energy expenditure

Int J Obes (London). 2010 Nov;34 (11):1634-43.

• Weight Loss – Tesofensine has produced twice the weight loss seen with currently marketed drugs.
  Obseity (Silver Spring). 2012 Mar;20 (3):553-61.doi:10.1038/oby.2011.197.Epub 2011 Jun 30.

Usage: Tesofensine (TE) is sold for in vitro testing and laboratory research purposes only. Pure Bio Labs offers select peptides for investigatory and research strategies. All peptides should be handled by licensed, qualified professionals.

Quality Assurance: Every Pure Bio Research Material undergoes rigorous testing to ensure purity, potency and consistency.